Vetbiolix
Products
Pipeline
Vetbiolix has built an innovative clinical-stage pipeline of 3 First-in -class assets, currently in clinical-stage in Human, acquired through exclusive & Worldwide Licensing deals with Human Biotech Companies.
- Innovative for Pets
- Major veterinary markets: Osteoarthritis, Periodontitis, Gut Motility Disorders
- Derisking approach (Clinical/CMC package from Human)
- Strong IP positions
VBX-2000 (ADENOSINE-A3 AGONIST) - Osteoarthritis
VBX-2400 Canine Osteoarthritis
VBX-2300 Feline Osteoarthritis
VBX-1000 (CATHEPSIN-K INHIBITOR) - Periodontitis
VBX-1200 Canine Periodontitis
VBX-1100 Feline Periodontitis
VBX-3000 (5HT-4 AGONIST) - Gut Motility Disorders
VBX-3500 Feline coprostasis & megacolon
VBX-3600 Canine GI motility disorders
NEW ASSET
Thanks to a validated track-record on licensing-in operation since Vetbiolix inception, we are actively seeking new opportunities for innovative assets currently in development for Human to develop them for Pets.
On-going programs with 3 assets for both Dogs & Cats
Stage of development from all Vetbiolix assets
Clinical POC studies positive to date
On-going Clinical Pilot studies (randomized, placebo-control, double-blind, dose-ranging, EU multicentric)
VBX-2000
VBX-2000 is a patented, First-in-class, oral small molecule, Adenosine-A3 Agonist treating cartilage degradation and reducing inflammation. This product is developed to answer to the crucial unmet medical need to treat the cause of Osteoarthritis (OA), i.e. cartilage degradation and inflammatory process.
Vetbiolix launched in 2024 a proof-of-concept (PoC) clinical study assessing the efficacy and safety of VBX-2000 in client-owned dogs with spontaneously developed OA. The results provide initial evidence of the efficacy of twice-a-day oral administration of VBX-2000 for 90 days against major clinical manifestations of OA. They provide the first proof of clinical effectiveness of a new therapeutic class for better management of osteoarthritis in dogs. With the safety profile observed throughout the treatment period, these results support further development of VBX-2000 in this indication. VBX-2000 is currently assessed in a regulatory, multricentric (Europe), randomized, double-blind, placebo-control, dose-ranging Pilot Clinical Study with Top-line results expected by Q3-2026.
end-points
CLINICAL TRIALS
Osteoarthritis is a significant cause of pain, lameness and morbidity in dogs and many others species, including humans. It is a multi-factorial, progressive, degenerative disease of synovial joints, affecting not only the articular cartilage but also other structures within the specific synovial joint. Degradation of articular cartilage, subchondral bone sclerosis, osteophytosis, varying degrees of synovitis, meniscal and ligament degeneration are all characteristics of the disease process. Existing therapeutic arsenal available for canine and feline OA are exclusively pain/symptomatic treatments : there is a crucial need for new treatment targeting joint/cartilage degradation.
VBX-2000 is currently assessed in a regulatory, multricentric (Europe), randomized, double-blind, placebo-control, dose-ranging Pilot Clinical Study.
VBX-2000 in Nutshell
- Pilot Clinical Study (placebo-ctrl): enrollment completed (118 patients) - Top line results by Q3-2026
- Clinical POC: highly statistically effect on primary and secondary end-points
- CMC-Pharmaceutical package adapted to Vet CoGs standards
- Very good safety profile
VBX-1000
VBX-1000 is a patented, first-in-class, oral small molecule, Cathepsin-K inhibitor for Periodontitis treatment. VBX-1000 is currently in development by Vetbiolix to obtain regulatory approval as the first veterinary treatment of Periodontitis (PD) in companion animals.
Periodontal disease (PD) is the most widespread oral disease in dogs, with studies showing that 60–97% of dogs have some degree of PD (1–4). PD is defined as plaque-induced immune-mediated damage to the periodontium, which anchors the tooth in the maxillary and mandibular bones. If left untreated, PD becomes a slowly evolving chronic inflammatory disease that first affects the gingiva (gingivitis) and then propagates to deeper structures of the periodontium, leading to progressive tooth attachment loss due to damage to the periodontal ligaments and loss of alveolar bone (periodontitis).
CLINICAL TRIALS
Vetbiolix launched in 2024 a proof-of-concept (PoC) clinical study assessing the efficacy and safety of VBX-1000 in client-owned dogs with spontaneously developed mild to moderate PD. The results provide initial evidence of the efficacy of once-a-day oral administration of VBX1000 for 90 days against major clinical manifestations of PD, supporting the regenerative action of VBX-1000 against alveolar bone loss. With the safety profile observed throughout the treatment period, these results support further development of VBX-1000 in this indication.
VBX-1000 is currently assessed in a regulatory, multricentric (Europe), randomized, double-blind, placebo-control, dose-ranging Pilot Clinical Study.
end-points
VBX-1000 in Nutshell
- Pilot Clinical Study (placebo-ctrl): enrollment on-going (60 patients) - Top line results by Q4-2026
- Oral treatment stopping bone resorption and contributing to bone regeneration.
- CMC-Pharmaceutical package adapted to Vet CoGs standards
- Very good safety profile